SecBot SecBot
8-K ·Filed Sep 2, 2026

RARE

Ultragenyx Pharmaceutical Inc.
BEARISH
Impact 8/10
Horizonimmediate Processed2mo ago SEC0001193125-26-380165
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

Expect a sharp sell-off on the Phase 3 miss as the market reprices the stock without apazunersen upside. Monitor the expense reduction plan details and any potential pipeline salvage moves; the commercial business support language suggests management is pivoting to existing revenue streams.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$14.85
T+0 close · Sep 2, 2026 · via day close
Latest settled
+2.49%
T+20 · $15.22 · next T+60 in 13d
Vs SPY
+3.68%
α at T+20
Latest observation
+19.11%
T+50 · FF3 residual α
  1. T+0 · Sep 3 $14.85entry
  2. T+1 · 2mo ago +3.03%α +3.42% · $15.30
  3. T+5 · 2mo ago −3.70%α −2.56% · $14.30
  4. T+20 · 7w ago +2.49%α +3.68% · $15.22
  5. T+51 · todayOpen
  6. T+60 · in 13d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ultragenyx announced that its Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome failed to meet the primary endpoint (Bayley-4 cognitive raw score) and the key secondary endpoint (MDRI). The company will evaluate the program's disposition and implement significant expense reductions while supporting its commercial business. This is a major pipeline setback for a company with a $2.5B market cap that was likely pricing in some probability of success for this high-profile asset.

Key Facts

  • Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score.
  • The study also failed the key secondary endpoint of net response in Multidomain Responder Index (MDRI).
  • No differences were observed between treated and control groups supporting efficacy in Bayley Cognition raw scores or MDRI.
  • Safety profile was consistent with Phase 1/2.
  • Company will evaluate the apazunersen program for disposition and implement significant expense reductions while supporting its growing commercial business.

Financial Impact

Phase 3 failure likely eliminates a major pipeline value driver; company will take significant expense reductions but no specific dollar amounts provided.

pipeline valueR&D expense

Risk Factors

  • Complete write-off of apazunersen program value
  • Potential for further pipeline setbacks if expense reductions impact other programs
  • Uncertainty around magnitude and timing of expense reductions

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-380165
Document: 0001193125-26-380165-index.html0001193125-26-380165
Document: 0001193125-26-380165.txt0001193125-26-380165

Track record

22 reports on RARE

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
  3. Nov 3, 202613d ago 8-K Mixed 6/10 No price data
  4. Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
  5. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
  6. Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
  7. Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
  8. Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
  9. Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
  10. Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 7h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 2, 2026